Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease

The neuroimmune axis of Alzheimer’s disease

(2023) Mehdi Jorfi et al.   Genome Medicine

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?

(2022) Christian Haass et al.   PLOS BIOLOGY

Alzheimer’s disease and its treatment by different approaches: A review

(2021) Sukriti Srivastava et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

FAF-DRVFL: Fuzzy activation function based deep random vector functional links network for early diagnosis of Alzheimer disease

(2021) Rahul Sharma et al.   APPLIED SOFT COMPUTING

Amyloid-type Protein Aggregation and Prion-like Properties of Amyloids

(2021) Dieter Willbold et al.   CHEMICAL REVIEWS

The Amyloid-β Pathway in Alzheimer’s Disease

(2021) Harald Hampel et al.   MOLECULAR PSYCHIATRY

Microglia and astrocyte involvement in neurodegeneration and brain cancer

(2021) Arthur A. Vandenbark et al.   Journal of Neuroinflammation

Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine

(2020) Md. Tanvir Kabir et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

(2020) Tiantian Guo et al.   Molecular Neurodegeneration

The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies

(2020) Myungjin Jo et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

The neuropathological diagnosis of Alzheimer’s disease

(2019) Michael A. DeTure et al.   Molecular Neurodegeneration

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

(2019) Justin M. Long et al.   CELL

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

(2018) Stina Tucker et al.   JOURNAL OF ALZHEIMERS DISEASE

An overview of FDA-approved vaccines & their innovators

(2017) Rebekah H. Griesenauer et al.   Expert Review of Vaccines

Familial Alzheimer's Disease Mutations within the Amyloid Precursor Protein Alter the Aggregation and Conformation of the Amyloid-β Peptide

(2017) Asa Hatami et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Locus coeruleus ablation exacerbates cognitive deficits, neuropathology, and lethality in P301S tau transgenic mice

(2017) Termpanit Chalermpalanupap et al.   JOURNAL OF NEUROSCIENCE

The Failure of Solanezumab — How the FDA Saved Taxpayers Billions

(2017) Chana A. Sacks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease

(2017) Reisuke H. Takahashi et al.   PATHOLOGY INTERNATIONAL

Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis

(2017) Jia-Jie Mo et al.   Annals of Clinical and Translational Neurology

Mitochondrial Alterations, Oxidative Stress and Neuroinflammation in Alzheimer's Disease

(2017) M. Verri et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: ACC-001 Clinical Trials Are Ongoing

(2017) J. Michael Ryan et al.   JOURNAL OF ALZHEIMERS DISEASE

GANTENERUMAB TREATMENT REDUCES BIOMARKERS OF NEURONAL AND SYNAPTIC DEGENERATION IN ALZHEIMER’S DISEASE

(2016) Kaj Blennow et al.   Alzheimers & Dementia

EFFICACY OF ACI-35, A LIPOSOMAL ANTI-PHOSPHO TAU VACCINE IN TWO DIFFERENT MOUSE MODELS OF ALZHEIMER’S DISEASE

(2016) Maria Pihlgren et al.   Alzheimers & Dementia

Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology

(2016) Adrian Olmos-Alonso et al.   BRAIN

“Small World” architecture in brain connectivity and hippocampal volume in Alzheimer’s disease: a study via graph theory from EEG data

(2016) Fabrizio Vecchio et al.   Brain Imaging and Behavior

Integrated biomarkers for depression in Alzheimer’s disease: a critical review

(2016) Sofia Wenzlera et al.   Current Alzheimer Research

Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer’s disease

(2016) Edward J. Goetzl et al.   FASEB JOURNAL

Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease

(2016) Florence Pasquier et al.   JOURNAL OF ALZHEIMERS DISEASE

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2016) Ross Penninkilampi et al.   Journal of Neuroimmune Pharmacology

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Failed Alzheimer’s trial does not kill leading theory of disease

(2016) Alison Abbott et al.   NATURE

Neurodegenerative disorders: Neural synchronization in Alzheimer's disease

(2016) Liviu Aron et al.   NATURE

Transfer of mitochondria from astrocytes to neurons after stroke

(2016) Kazuhide Hayakawa et al.   NATURE

Origin, fate and dynamics of macrophages at central nervous system interfaces

(2016) Tobias Goldmann et al.   NATURE IMMUNOLOGY

Rethinking on the concept of biomarkers in preclinical Alzheimer’s disease

(2016) Valentina Berti et al.   NEUROLOGICAL SCIENCES

Therapeutic strategies for Alzheimer's disease in clinical trials

(2016) Justyna Godyń et al.   Pharmacological Reports

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

(2016) Adrian Ivanoiu et al.   Alzheimers Research & Therapy

Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?

(2015) Isabelle St-Amour et al.   ACTA NEUROPATHOLOGICA

Emerging Concepts in Alzheimer's Disease

(2015) Harry V. Vinters   Annual Review of Pathology-Mechanisms of Disease

Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia

(2015) Tobias Skillbäck et al.   BRAIN

Early investigational drugs targeting tau protein for the treatment of Alzheimer’s disease

(2015) Keshav Anand et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Erratum: Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?

(2015) David A Loeffler   Journal of Neuroinflammation

IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia

(2015) Shawn Kile et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Neuroinflammation in Alzheimer's disease

(2015) Michael T Heneka et al.   LANCET NEUROLOGY

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

(2015) Markus Mandler et al.   Molecular Neurodegeneration

Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia

(2015) Kumar B. Rajan et al.   NEUROLOGY

Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death

(2015) Daniela Rossi   PROGRESS IN NEUROBIOLOGY

Prion-like features of misfolded Aβ and tau aggregates

(2015) Rodrigo Morales et al.   VIRUS RESEARCH

Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain

(2015) Shuko Takeda et al.   Nature Communications

The dynamics of monocytes and microglia in Alzheimer’s disease

(2015) Peter Thériault et al.   Alzheimers Research & Therapy

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease

(2015) Martin R Farlow et al.   Alzheimers Research & Therapy

Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

(2015) Aaron Ritter et al.   Frontiers in Neurology

Endoplasmic Reticulum Stress Induced by Zinc Oxide Nanoparticles Is an Earlier Biomarker for Nanotoxicological Evaluation

(2014) Rui Chen et al.   ACS Nano

Aβ immunotherapy for Alzheimer’s disease: effects on apoE and cerebral vasculopathy

(2014) Kenji Sakai et al.   ACTA NEUROPATHOLOGICA

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

(2014) Jeffrey Cummings et al.   Alzheimers & Dementia

Amyloid Imaging in Aging and Dementia: Testing the Amyloid HypothesisIn Vivo

(2014) G. D. Rabinovici et al.   BEHAVIOURAL NEUROLOGY

Immunotherapy for Alzheimer's disease

(2014) Thomas Wisniewski et al.   BIOCHEMICAL PHARMACOLOGY

Convergence of pathology in dementia with Lewy bodies and Alzheimer’s disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease

(2014) Ashley R. Winslow et al.   BRAIN

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

(2014) Ludovic Collin et al.   BRAIN

Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease

(2014) Norman Relkin   JOURNAL OF CLINICAL IMMUNOLOGY

Amyloid-ß-directed immunotherapy for Alzheimer's disease

(2014) L. Lannfelt et al.   JOURNAL OF INTERNAL MEDICINE

Brain-Derived Neurotrophic Factor in Alzheimer’s Disease: Risk, Mechanisms, and Therapy

(2014) Jing-Hui Song et al.   MOLECULAR NEUROBIOLOGY

Microglial priming in neurodegenerative disease

(2014) V. Hugh Perry et al.   Nature Reviews Neurology

Spreading of amyloid-β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance

(2014) Jakob Domert et al.   NEUROBIOLOGY OF DISEASE

The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

(2014) Reisa Sperling et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human Astrocytes: Secretome Profiles of Cytokines and Chemokines

(2014) Sung S. Choi et al.   PLoS One

Overrepresentation of Glutamate Signaling in Alzheimer's Disease: Network-Based Pathway Enrichment Using Meta-Analysis of Genome-Wide Association Studies

(2014) Eduardo Pérez-Palma et al.   PLoS One

Active immunotherapy options for Alzheimer’s disease

(2014) Bengt Winblad et al.   Alzheimers Research & Therapy

Biochemical Distribution of Tau Protein in Synaptosomal Fraction of Transgenic Mice Expressing Human P301L Tau

(2014) Naruhiko Sahara et al.   Frontiers in Neurology

GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis

(2013) Min-Chi Ku et al.   ACTA NEUROPATHOLOGICA

Microglia actions in Alzheimer’s disease

(2013) Stefan Prokop et al.   ACTA NEUROPATHOLOGICA

Intracranial administration of Gammagard IVIg lowers amyloid and modulates neuroinflammatory profiles along a different time-course than anti-beta-amyloid IgG: Implications for mechanism of action

(2013) Donna Wilcock et al.   Alzheimers & Dementia

The future of blood-based biomarkers for Alzheimer's disease

(2013) Kim Henriksen et al.   Alzheimers & Dementia

Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies

(2013) Hanna Rosenmann   Current Alzheimer Research

Intravenous immunoglobulin and Alzheimer’s disease: what now?

(2013) David A Loeffler   Journal of Neuroinflammation

Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease

(2013) Alberto Serrano-Pozo et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Immunotherapy for Alzheimer’s disease: hoops and hurdles

(2013) Cynthia A Lemere   Molecular Neurodegeneration

CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology

(2013) Elizabeth M Bradshaw et al.   NATURE NEUROSCIENCE

Immunotherapy for Alzheimer’s Disease

(2013) Martin R. Farlow et al.   NEUROLOGIC CLINICS

Microglia as Dynamic and Essential Components of the Amyloid Hypothesis

(2013) Sam Gandy et al.   NEURON

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

(2013) Kiran Yanamandra et al.   NEURON

Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease

(2013) Kaj Blennow et al.   NEUROPSYCHOPHARMACOLOGY

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

(2013) Clara Theunis et al.   PLoS One

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

(2013) Jens Moreth et al.   Immunity & Ageing

Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers

(2013) Xiao Da et al.   NeuroImage-Clinical

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification by APOE Genotype

(2012) Madhav Thambisetty et al.   BIOLOGICAL PSYCHIATRY

Amyloid-β Immunotherapy for Alzheimers Disease

(2012) H.J. Fu et al.   CNS & Neurological Disorders-Drug Targets

Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease

(2012) Suzanne E. Hickman et al.   CNS & Neurological Disorders-Drug Targets

Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer

(2012) Petra et al.   Frontiers in Bioscience-Landmark

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Active immunotherapy for Alzheimer's disease

(2012) Thomas Wisniewski   LANCET NEUROLOGY

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

The many faces of α-synuclein: from structure and toxicity to therapeutic target

(2012) Hilal A. Lashuel et al.   NATURE REVIEWS NEUROSCIENCE

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

(2012) Thorlakur Jonsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microglial microvesicle secretion and intercellular signaling

(2012) Elena Turola   Frontiers in Physiology

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Managing Cognitive Dysfunction through the Continuum of Alzheimerʼs Disease

(2011) Julien Delrieu et al.   CNS DRUGS

Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease

(2011) Chuanyu Li et al.   Current Alzheimer Research

Obesity is associated with hypothalamic injury in rodents and humans

(2011) Joshua P. Thaler et al.   JOURNAL OF CLINICAL INVESTIGATION

Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load

(2011) Qingyou Li et al.   Journal of Neuroimmune Pharmacology

The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis

(2011) Jie Zhao et al.   Journal of Neuroinflammation

Progress in Alzheimer’s disease

(2011) Daniela Galimberti et al.   JOURNAL OF NEUROLOGY

The Second-Generation Active A  Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

(2011) C. Wiessner et al.   JOURNAL OF NEUROSCIENCE

Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-  Immunotherapy

(2011) A. Wang et al.   JOURNAL OF NEUROSCIENCE

Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity

(2011) Fuxiang Bao et al.   NEUROBIOLOGY OF AGING

Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

(2011) Susann Cattepoel et al.   PLoS One

In vivo demonstration that  -synuclein oligomers are toxic

(2011) B. Winner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disease-modifying treatments for Alzheimer’s disease

(2011) Daniela Galimberti et al.   Therapeutic Advances in Neurological Disorders

Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease

(2010) Kaj Blennow et al.   Alzheimers & Dementia

Direct observation of the kinetic mechanisms for Aß peptide aggregation: Towards elucidating Alzheimer plaque dissolution

(2010) Norma A. Alcantar et al.   Alzheimers & Dementia

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

(2010) Moran Boimel et al.   EXPERIMENTAL NEUROLOGY

Immunotherapy for Alzheimer’s disease

(2010) D. Morgan   JOURNAL OF INTERNAL MEDICINE

Synergistic Interactions between A , Tau, and  -Synuclein: Acceleration of Neuropathology and Cognitive Decline

(2010) L. K. Clinton et al.   JOURNAL OF NEUROSCIENCE

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

(2010) A. Boutajangout et al.   JOURNAL OF NEUROSCIENCE

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE

(2010) D. T. Laskowitz et al.   NEUROLOGY

Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and A  deposition in an Alzheimer mouse model with diabetes

(2010) S. Takeda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical applications of intravenous immunoglobulins in neurology

(2009) R. A. C. Hughes et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Targeting Aβ and tau in Alzheimer's disease, an early interim report

(2009) Todd E. Golde et al.   EXPERIMENTAL NEUROLOGY

Tau oligomers and aggregation in Alzheimer’s disease

(2009) Marco A. Meraz-Ríos et al.   JOURNAL OF NEUROCHEMISTRY

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

(2009) A. Schneeberger et al.   Journal of Nutrition Health & Aging

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

(2009) Denise Harold et al.   NATURE GENETICS

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

(2009) H. Fillit et al.   NEUROLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer' Disease: The Role of the Immune System in Clearance of Aβ from the Brain

(2008) Delphine Boche et al.   BRAIN PATHOLOGY

Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice

(2008) Irina Petrushina et al.   Journal of Neuroinflammation

Lack of Pathology in a Triple Transgenic Mouse Model of Alzheimer's Disease after Overexpression of the Anti-Apoptotic Protein Bcl-2

(2008) T. T. Rohn et al.   JOURNAL OF NEUROSCIENCE

Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis

(2008) Michael Pride et al.   Neurodegenerative Diseases

Biochemical markers in persons with preclinical familial Alzheimer disease

(2008) J. M. Ringman et al.   NEUROLOGY